Financials data is unavailable for this security.
View more
Year on year Eli Lilly and Co had net income fall -16.08% from 6.24bn to 5.24bn despite revenues that grew 19.56% from 28.54bn to 34.12bn over the same period.
Gross margin | 80.16% |
---|---|
Net profit margin | 17.08% |
Operating margin | 20.80% |
Return on assets | 10.48% |
---|---|
Return on equity | 51.15% |
Return on investment | 14.92% |
More ▼
Cash flow in USDView more
In 2023, Eli Lilly and Co increased its cash reserves by 36.36%, or 751.60m. The company earned 4.24bn from its operations for a Cash Flow Margin of 12.43%. In addition the company generated 3.50bn cash from financing while 7.15bn was spent on investing.
Cash flow per share | 8.54 |
---|---|
Price/Cash flow per share | 94.99 |
Book value per share | 13.48 |
---|---|
Tangible book value per share | 1.17 |
More ▼
Balance sheet in USDView more
Current ratio | 1.35 |
---|---|
Quick ratio | 1.03 |
Total debt/total equity | 2.05 |
---|---|
Total debt/total capital | 0.6702 |
More ▼
Growth rates in USD
SmartText is unavailable
Div yield(5 year avg) | 1.36% |
---|---|
Div growth rate (5 year) | 14.97% |
Payout ratio (TTM) | 71.20% |
EPS growth(5 years) | 12.51 |
---|---|
EPS (TTM) vs TTM 1 year ago | 7.85 |
More ▼